Sanket S Dhruva

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7503628/publications.pdf

Version: 2024-02-01

98	2,260	304602	254106
papers	citations	22 h-index	43 g-index

103	103	103	2982
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. JAMA - Journal of the American Medical Association, 2020, 323, 734.	3.8	260
2	Feasibility of Using Real-World Data to Replicate Clinical Trial Evidence. JAMA Network Open, 2019, 2, e1912869.	2.8	167
3	Strength of Study Evidence Examined by the FDA in Premarket Approval of Cardiovascular Devices. JAMA - Journal of the American Medical Association, 2009, 302, 2679.	3.8	157
4	Coronary Computed Tomography Angiography vs Functional Stress Testing for Patients With Suspected Coronary Artery Disease. JAMA Internal Medicine, 2017, 177, 1623.	2.6	116
5	2016 Update on Medical Overuse. JAMA Internal Medicine, 2016, 176, 1687.	2.6	92
6	Enhancing the prediction of acute kidney injury risk after percutaneous coronary intervention using machine learning techniques: A retrospective cohort study. PLoS Medicine, 2018, 15, e1002703.	3.9	91
7	Gender Bias in Studies for Food and Drug Administration Premarket Approval of Cardiovascular Devices. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 165-171.	0.9	71
8	2017 Update on Medical Overuse. JAMA Internal Medicine, 2018, 178, 110.	2.6	61
9	2019 Update on Medical Overuse. JAMA Internal Medicine, 2019, 179, 1568.	2.6	60
10	Revisiting Essure â€" Toward Safe and Effective Sterilization. New England Journal of Medicine, 2015, 373, e17.	13.9	59
11	CMS's Landmark Decision on CT Colonography â€" Examining the Relevant Data. New England Journal of Medicine, 2009, 360, 2699-2701.	13.9	58
12	Use of Mechanical Circulatory Support Devices Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. JAMA Network Open, 2021, 4, e2037748.	2.8	54
13	Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis. BMJ: British Medical Journal, 2018, 361, k2031.	2.4	52
14	Aggregating multiple real-world data sources using a patient-centered health-data-sharing platform. Npj Digital Medicine, 2020, 3, 60.	5.7	51
15	Update on Pediatric Overuse. Pediatrics, 2017, 139, .	1.0	40
16	2018 Update on Medical Overuse. JAMA Internal Medicine, 2019, 179, 240.	2.6	40
17	Accelerated Approval and Possible Withdrawal of Midodrine. JAMA - Journal of the American Medical Association, 2010, 304, 2172.	3.8	36
18	Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for HeartÂFailure. Journal of the American College of Cardiology, 2022, 79, 2516-2525.	1.2	34

#	Article	IF	Citations
19	Update on Medical Practices That Should Be Questioned in 2015. JAMA Internal Medicine, 2015, 175, 1960.	2.6	33
20	2017 Update on Pediatric Medical Overuse. JAMA Pediatrics, 2018, 172, 482.	3.3	32
21	Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports. BMJ, The, 2015, 350, h2613-h2613.	3.0	30
22	Evaluating Sex Differences in Medical Device Clinical Trials. JAMA - Journal of the American Medical Association, 2012, 307, 1145.	3.8	28
23	Age of Data at the Time of Publication of Contemporary Clinical Trials. JAMA Network Open, 2018, 1, e181065.	2.8	23
24	The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 1066-1076.	0.5	22
25	New and incremental FDA black box warnings from 2008 to 2015. Expert Opinion on Drug Safety, 2018, 17, 117-123.	1.0	21
26	Characteristics of Clinical Studies Used for US Food and Drug Administration Approval of High-Risk Medical Device Supplements. JAMA - Journal of the American Medical Association, 2017, 318, 619.	3.8	20
27	Early experience with the FDAâ€™s Breakthrough Devices program. Nature Biotechnology, 2020, 38, 933-938.	9.4	20
28	Medicare Formulary Coverage Restrictions for Prescription Opioids, 2006 to 2015. Annals of Internal Medicine, 2017, 167, 895.	2.0	19
29	Moving From Substantial Equivalence to Substantial Improvement for 510(k) Devices. JAMA - Journal of the American Medical Association, 2019, 322, 927.	3.8	19
30	Real-World Evidence: Promise and Peril For Medical Product Evaluation. P and T, 2018, 43, 464-472.	1.0	19
31	Fulfilling the Promise of Unique Device Identifiers. Annals of Internal Medicine, 2018, 169, 183.	2.0	18
32	2018 Update on Pediatric Medical Overuse. JAMA Pediatrics, 2019, 173, 379.	3.3	18
33	Systolic Blood Pressure Response in SPRINT (Systolic Blood Pressure Intervention Trial) and ACCORD (Action to Control Cardiovascular Risk in Diabetes): A Possible Explanation for Discordant Trial Results. Journal of the American Heart Association, 2017, 6, .	1.6	16
34	Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019. JAMA Internal Medicine, 2022, 182, 185.	2.6	16
35	Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent) Tj ETQq1 1 0.784314 rgBT /O	1.3	15
36	Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments. JAMA Network Open, 2019, 2, e193410.	2.8	15

#	Article	IF	Citations
37	Clinical Evidence Supporting US Food and Drug Administration Clearance of Novel Therapeutic Devices via the De Novo Pathway Between 2011 and 2019. JAMA Internal Medicine, 2020, 180, 1701.	2.6	15
38	Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 1230-1238.	0.5	14
39	Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis. BMC Medicine, 2019, 17, 117.	2.3	14
40	2019 Update on Pediatric Medical Overuse. JAMA Pediatrics, 2020, 174, 375.	3.3	14
41	Feasibility of capturing real-world data from health information technology systems at multiple centers to assess cardiac ablation device outcomes: A fit-for-purpose informatics analysis report. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 2241-2250.	2.2	14
42	Championing Effectiveness Before Cost-Effectiveness â^—. JACC: Heart Failure, 2016, 4, 376-379.	1.9	13
43	Medical Device Regulation: Time to Improve Performance. PLoS Medicine, 2012, 9, e1001277.	3.9	12
44	Inclusion of Demographic-Specific Information in Studies Supporting US Food & Drug Administration Approval of High-Risk Medical Devices. JAMA Internal Medicine, 2017, 177, 1390.	2.6	12
45	Real-World Data on Heart Failure Readmission Reduction. Journal of the American College of Cardiology, 2017, 69, 2366-2368.	1.2	11
46	Evolution of Medicare Formulary Coverage Changes for Antithrombotic Therapies After Guideline Updates. Circulation, 2019, 140, 1227-1230.	1.6	11
47	Factors associated with remote monitoring adherence for cardiovascular implantable electronic devices. Heart Rhythm, 2022, 19, 1499-1507.	0.3	11
48	FDA regulation of cardiovascular devices and opportunities for improvement. Journal of Interventional Cardiac Electrophysiology, 2013, 36, 99-105.	0.6	10
49	Attribution of Adverse Events Following Coronary Stent Placement Identified Using Administrative Claims Data. Journal of the American Heart Association, 2020, 9, e013606.	1.6	10
50	Medicare Prescription Drug Plan Coverage of Hormone Therapies Used by Transgender Individuals. LGBT Health, 2020, 7, 137-145.	1.8	10
51	Changing FDA Approval Standards: Ethical Implications for Patient Consent. Journal of General Internal Medicine, 2021, 36, 3212-3214.	1.3	10
52	Reporting of Death in US Food and Drug Administration Medical Device Adverse Event Reports in Categories Other Than Death. JAMA Internal Medicine, 2021, 181, 1217.	2.6	10
53	Inclusion of Training Patients in US Food and Drug Administration Premarket Approval Cardiovascular Device Studies. Archives of Internal Medicine, 2011, 171, 534-9.	4.3	9
54	Transcatheter Aortic Valve Replacement in Younger Individuals. JAMA Internal Medicine, 2017, 177, 159.	2.6	9

#	Article	IF	Citations
55	Trends in Within-Class Changes in US Average Wholesale Prices for Brand-Name Medications for Common Conditions From 2015 to 2020. JAMA Network Open, 2021, 4, e2035064.	2.8	9
56	Medicareâ€™s New Device-Coverage Pathway â€" Breakthrough or Breakdown?. New England Journal of Medicine, 2021, 384, e43.	13.9	9
57	Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016. Medicine (United States), 2018, 97, e12715.	0.4	8
58	Age-treatment subgroup analyses in Cochrane intervention reviews: a meta-epidemiological study. BMC Medicine, 2019, 17, 188.	2.3	8
59	Evaluation of technologies approved for supplemental payments in the United States. BMJ: British Medical Journal, 2019, 365, l2190.	2.4	8
60	Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump for Cardiogenic Shockâ€"Reply. JAMA - Journal of the American Medical Association, 2020, 324, 303.	3.8	8
61	Characteristics, interventions and outcomes of patients with valvular heart disease hospitalised in China: a cross-sectional study. BMJ Open, 2021, 11, e052946.	0.8	8
62	Use of Mechanical Cardiopulmonary Resuscitation Devices for Out-of-Hospital Cardiac Arrest, 2010-2016. JAMA Network Open, 2019, 2, e1913298.	2.8	7
63	The Core Value of Cost-Effectiveness Analysesâ^—. Journal of the American College of Cardiology, 2016, 67, 39-41.	1.2	6
64	Controversies in Diagnostic Imaging of Patients With Suspected Stable and Acute Chest Pain Syndromes. JACC: Cardiovascular Imaging, 2019, 12, 1254-1278.	2.3	6
65	For the Patient with â€œLow-risk Chest Painâ€â€"How Low Is Low?. Academic Radiology, 2016, 23, 1587-1591.	1.3	5
66	Assessment of Clinical Trial Evidence for High-Risk Cardiovascular Devices Approved Under the Food and Drug Administration Priority Review Program. JAMA Internal Medicine, 2018, 178, 1418.	2.6	5
67	Medicare Formulary Coverage and Restrictions for Opioid Potentiators from 2013 to 2017. Journal of General Internal Medicine, 2019, 34, 518-520.	1.3	5
68	Medicare Formulary Coverage of Brand-Name Drugs and Therapeutically Interchangeable Generics. Journal of General Internal Medicine, 2020, 35, 1928-1930.	1.3	5
69	Mandatory Registration and Results Reporting of Real-World Evidence Studies of FDA-Regulated Medical Products. Mayo Clinic Proceedings, 2020, 95, 2609-2611.	1.4	5
70	US Food and Drug Administrationâ€"Mandated Postmarketing Studies for High-risk Cardiovascular Devices Approved 2015-2019. JAMA Internal Medicine, 2022, 182, 556.	2.6	5
71	Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies. Journal of General Internal Medicine, 2019, 34, 2319-2321.	1.3	4
72	Assessment of FDA Approval for New High-risk Therapeutic Devices Not Meeting Pivotal Study Primary End Points, 2016-2020. JAMA Internal Medicine, 2021, 181, 1409.	2.6	4

#	Article	IF	Citations
73	A 510(k) ancestry of robotic surgical systems. International Journal of Surgery, 2022, 98, 106229.	1.1	4
74	Evaluation of cardiovascular implantable electronic device leads post implant: ElectroPhysiology Predictable And SuStainable Implementation Of National Registries (EP PASSION). Journal of Interventional Cardiac Electrophysiology, 2022, , 1.	0.6	4
75	Feasibility of using real-world data in the evaluation of cardiac ablation catheters: a test-case of the National Evaluation System for Health Technology Coordinating Center. BMJ Surgery, Interventions, and Health Technologies, 2021, 3, e000089.	0.6	4
76	Application of Medicareâ€™s New Technology Add-on Payment Program for Blinatumomab. JAMA Oncology, 2016, 2, 165.	3.4	3
77	Accurate estimation of cardiovascular risk in a non-diabetic adult: detecting and correcting the error in the reported Framingham Risk Score for the Systolic Blood Pressure Intervention Trial population. BMJ Open, 2018, 8, e021685.	0.8	3
78	A Successful but Underused Strategy for Reducing Low-Value Care: Stop Paying for It. JAMA Internal Medicine, 2020, 180, 532.	2.6	3
79	Coverage of Transvenous Pulmonary Embolectomy â€” Medicareâ€™s Missed Opportunity for Evidence Generation. New England Journal of Medicine, 2022, 386, 904-906.	13.9	3
80	Association between FDA black box warnings and Medicare formulary coverage changes. American Journal of Managed Care, 2017, 23, e310-e315.	0.8	3
81	Gender Bias in Studies for FDA Premarket Approval of Cardiovascular Devices. Current Cardiovascular Risk Reports, 2014, 8, 1.	0.8	2
82	Commentary on Bertagnolli et al.: Leveraging electronic health record data for clinical trialsâ€”a brave new world. Clinical Trials, 2020, 17, 243-246.	0.7	2
83	Endoscopic transmission of carbapenem-resistant Enterobacteriaceae: implications for U.S. Food and Drug Administration approval and postmarket surveillance of endoscopic devices. Gastrointestinal Endoscopy, 2021, 93, 231-238.	0.5	2
84	Media Portrayals of Extracorporeal Membrane Oxygenation. JAMA Internal Medicine, 2021, 181, 394.	2.6	2
85	Physical activity, patient-reported symptoms, and clinical events: Insights into postprocedural recovery from personal digital devices. Cardiovascular Digital Health Journal, 2021, 2, 212-221.	0.5	2
86	Clinical studies sponsored by digital health companies participating in the FDAâ€™s Precertification Pilot Program: A cross-sectional analysis. Clinical Trials, 2022, 19, 119-122.	0.7	2
87	Resource Utilization Following Coronary Computed Tomographic Angiography and Stress Echocardiography in Patients Presenting to the Emergency Department With Chest Pain. American Journal of Cardiology, 2022, 163, 8-12.	0.7	2
88	Strategies to Manage Drugs and Devices Approved Based on Limited Evidence: Results of a Modified Delphi Panel. Clinical Pharmacology and Therapeutics, 2022, 111, 1307-1314.	2.3	2
89	Medical Device User Fee Reauthorization â€” Back to Basics or Looking Ahead?. New England Journal of Medicine, 2022, 387, 196-199.	13.9	2
90	The Art of the Deal: Negotiating Consult Conflict. American Journal of Medicine, 2020, 133, 889-891.	0.6	1

#	Article	IF	Citations
91	Outcomes-Driven Clinical Phenotyping in Cardiogenic Shock using a Mixture of Experts. , 2021, , .		1
92	Expertsâ€™ Views on FDA Regulatory Standards for Drug and High-Risk Medical Devices: Implications for Patient Care. Journal of General Internal Medicine, 2022, , 1.	1.3	1
93	Heart Watch Study: protocol for a pragmatic randomised controlled trial. BMJ Open, 2021, 11, e054550.	0.8	1
94	Letter by Dhruva and Redberg Regarding Article, â€œSex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Programâ€• Circulation, 2017, 135, e20-e21.	1.6	0
95	Medical Overuse of Prostate-Specific Antigen Testing and Overprescription of Antibioticsâ€”Reply. JAMA Internal Medicine, 2018, 178, 432.	2.6	0
96	Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 1201-1217.	0.5	0
97	GLASS(Y) Half-Full. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007690.	0.9	0
98	Letter by Dhruva and Redberg Regarding Article, â€œAmplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trialâ€• Circulation, 2022, 145, e845-e846.	1.6	0